| Tomassoni, Gery |
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation |
|
|
| Active, not recruiting | 4 | 3000 | US | Dronedarone, Multaq | American Heart Association, Duke Clinical Research Institute, Sanofi | Atrial Fibrillation | 06/24 | 12/24 | | |
| Active, not recruiting | N/A | 1686 | Europe, Canada, Japan, US, RoW | SyncAV programmed ON, Fixed AV delay | Abbott Medical Devices | Congestive Heart Failure | 06/25 | 12/25 | | |
| Recruiting | N/A | 300 | US | OPTIMIZER® Integra CCM-D System (Treatment Arm) | Impulse Dynamics | Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy, Non-ischemic Cardiomyopathy, Ischemic Cardiomyopathy, Sudden Cardiac Arrest, Arrhythmias, Cardiac, Ventricular Tachycardia, Ventricular Fibrillation | 06/24 | 12/25 | | |
| Recruiting | N/A | 2650 | Europe, Canada, Japan, US, RoW | Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC | Abbott Medical Devices | Atrial Fibrillation, Stroke, Bleeding | 08/27 | 08/30 | | |
ADVANTAGE AF, NCT05443594: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation |
|
|
| Active, not recruiting | N/A | 669 | Europe, Canada, US | Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System | Boston Scientific Corporation | Persistent Atrial Fibrillation | 03/25 | 03/25 | | |
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy |
|
|
| Recruiting | N/A | 620 | US | OPTIMIZER Smart System | Impulse Dynamics | Heart Failure | 03/26 | 03/26 | | |
LUX-Dx TRENDS, NCT04790344: Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System. |
|
|
| Active, not recruiting | N/A | 525 | US | Investigational LUX-Dx ICM Implant | Boston Scientific Corporation | Heart Failure | 05/26 | 06/26 | | |
| Dukes, Jonathan W |
AVANT GUARD, NCT06096337: Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation |
|
|
| Recruiting | N/A | 387 | Europe, Canada, US, RoW | FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, and Dofetilide | Boston Scientific Corporation | Persistent Atrial Fibrillation | 12/25 | 12/27 | | |
DISRUPT-AF, NCT06335082: A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF |
|
|
| Not yet recruiting | N/A | 900 | US | Pulsed Field Ablation | Heart Rhythm Clinical and Research Solutions, LLC, Boston Scientific Corporation | Atrial Fibrillation | 11/26 | 01/27 | | |
| Recruiting | N/A | 900 | US | Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download, Medication intervention | Medtronic Cardiac Rhythm and Heart Failure | Heart Failure NYHA Class II, Heart Failure NYHA Class III | 04/25 | 04/25 | | |
NCT04496518: Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS) |
|
|
| Recruiting | N/A | 2200 | Europe, US | Intrinsic Antitachycardia Pacing (iATP) Therapy | Medtronic | Ventricular Tachycardia | 01/25 | 01/27 | | |
NCT04489225: Personalized Therapy Study - HFRS (TriageHF) Post Approval Study |
|
|
| Recruiting | N/A | 2200 | Europe, US | Observational | Medtronic | Heart Failure | 01/25 | 01/27 | | |
ASQ, NCT04024943: Personalized Therapy Study - Attain Stability Quad Post-Approval Study |
|
|
| Active, not recruiting | N/A | 1008 | Europe, US | Quadripolar LV Lead, Medtronic CRT-P, Medtronic CRT-D | Medtronic | Heart Failure | 01/27 | 04/27 | | |
NCT04088071: Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation |
|
|
| Recruiting | N/A | 15000 | US | Catheter ablation | Heart Rhythm Clinical and Research Solutions, LLC, Biosense Webster, Inc. | Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation | 12/27 | 12/27 | | |
| Cheung, Jim W |
REACT-AF, NCT05836987: The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation |
|
|
| Recruiting | 3 | 5350 | US | AFSW Guided DOAC, Apple Watch, Continuous DOAC therapy, Oral Anticoagulation therapy | Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI) | Atrial Fibrillation | 07/29 | 07/29 | | |
NCT04170894: Radiofrequency Ablation of Atrial Fibrillation Under Apnea |
|
|
| Active, not recruiting | N/A | 128 | US | Periods of Apnea, Control Arm - No Periods of Apnea | Weill Medical College of Cornell University, Northwell Health, The Methodist Hospital Research Institute | Atrial Fibrillation | 03/22 | 12/24 | | |
AVANT GUARD, NCT06096337: Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation |
|
|
| Recruiting | N/A | 387 | Europe, Canada, US, RoW | FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, and Dofetilide | Boston Scientific Corporation | Persistent Atrial Fibrillation | 12/25 | 12/27 | | |
NCT05977049: Psychosocial Support for Patients With Takotsubo Syndrome |
|
|
| Recruiting | N/A | 48 | US | Takotsubo Support Group | Weill Medical College of Cornell University | Takotsubo Cardiomyopathy | 08/24 | 01/25 | | |
ADVANTAGE AF, NCT05443594: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation |
|
|
| Active, not recruiting | N/A | 669 | Europe, Canada, US | Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System | Boston Scientific Corporation | Persistent Atrial Fibrillation | 03/25 | 03/25 | | |
| Issa, Ziad |
HEAL, NCT04645173: Comparison of Participants Who Received a CanGaroo® Envelope, TYRX™ Envelope, or no Envelope During CIED Implantation |
|
|
| Completed | N/A | 46 | US | CIED envelope | Aziyo Biologics, Inc. | Cardiac Disease | 10/23 | 12/23 | | |
AVANT GUARD, NCT06096337: Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation |
|
|
| Recruiting | N/A | 387 | Europe, Canada, US, RoW | FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, and Dofetilide | Boston Scientific Corporation | Persistent Atrial Fibrillation | 12/25 | 12/27 | | |
INTERRUPT AF, NCT03729830: Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation |
|
|
| Completed | N/A | 415 | Europe, Japan, US, RoW | Boston Scientific Open Irrigated Ablation Catheters | Boston Scientific Corporation | Paroxysmal Atrial Fibrillation | 05/24 | 05/24 | | |
ADVANTAGE AF, NCT05443594: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation |
|
|
| Active, not recruiting | N/A | 669 | Europe, Canada, US | Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System | Boston Scientific Corporation | Persistent Atrial Fibrillation | 03/25 | 03/25 | | |
| Suspended | N/A | 105 | US | Pacemaker PLR + TRT ON, Pacemaker PLR ON | Medtronic Cardiac Rhythm and Heart Failure | Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy | 01/26 | 01/26 | | |
| Young, Jennifer |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
NCT03643224: DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation |
|
|
| Active, not recruiting | N/A | 376 | Europe, Canada, US, RoW | Radiofrequency Ablation | Medtronic Cardiac Rhythm and Heart Failure | Persistent Atrial Fibrillation, Atrial Fibrillation | 10/24 | 12/24 | | |
ADVANTAGE AF, NCT05443594: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation |
|
|
| Active, not recruiting | N/A | 669 | Europe, Canada, US | Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System | Boston Scientific Corporation | Persistent Atrial Fibrillation | 03/25 | 03/25 | | |
| Recruiting | N/A | 500 | US | Encore PFO closure device, FDA-approved PFO closure device | Encore Medical Inc., Bright Research Partners, Yale Cardiovascular Research Group | Patent Foramen Ovale, Cryptogenic Stroke | 04/25 | 10/29 | | |
IONA-MM, NCT04458831: A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) |
|
|
| Recruiting | N/A | 1200 | Europe, Japan, US, RoW | isatuximab SAR650984, Sarclisa, Pomalidomide, Pomalyst, Dexamethasone, Carfilzomib | Sanofi | Plasma Cell Myeloma | 02/26 | 02/26 | | |
| Osorio, Jose |
PLEA, NCT04216667: Posterior Wall And Left Atrial Appendage Empiric Electrical Isolation for Non-Paroxysmal Atrial Fibrillation |
|
|
| Terminated | N/A | 124 | Europe, US, RoW | Catheter ablation | Montefiore Medical Center, Biosense Webster, Inc. | Atrial Fibrillation | 06/23 | 06/23 | | |
AVANT GUARD, NCT06096337: Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation |
|
|
| Recruiting | N/A | 387 | Europe, Canada, US, RoW | FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, and Dofetilide | Boston Scientific Corporation | Persistent Atrial Fibrillation | 12/25 | 12/27 | | |
| Active, not recruiting | N/A | 200 | Europe, Canada, US | Adagio AF Cryoablation System (iCLAS™) | Adagio Medical | Persistent Atrial Fibrillation | 08/23 | 08/24 | | |
NCT05242250: Real-World Evidence Registry to Assess Outcomes of Catheter Ablation for Atrial Fibrillation (DYNAMIC AF Registry) |
|
|
| Terminated | N/A | 392 | US | Catheter Ablation, Atrial Fibrillation Ablation | Heart Rhythm Clinical and Research Solutions, LLC, Abbott | Atrial Fibrillation | 12/23 | 12/23 | | |
ADVANTAGE AF, NCT05443594: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation |
|
|
| Active, not recruiting | N/A | 669 | Europe, Canada, US | Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System | Boston Scientific Corporation | Persistent Atrial Fibrillation | 03/25 | 03/25 | | |
NCT04088071: Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation |
|
|
| Recruiting | N/A | 15000 | US | Catheter ablation | Heart Rhythm Clinical and Research Solutions, LLC, Biosense Webster, Inc. | Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation | 12/27 | 12/27 | | |
| Hounshell, Troy |
NCT03811795: Cryoballoon vs. Rhythmia Guided Ablation for Recurrent AFib |
|
|
| Recruiting | N/A | 50 | US | ECG monitoring with a Kardia Mobile monitor | Valley Health System | Atrial Fibrillation | 11/22 | 11/23 | | |
| Recruiting | N/A | 1000 | US | WATCHMAN FLX Pro LAAC Device, Left Atrial Appendage Closure | Boston Scientific Corporation | Atrial Fibrillation, Bleeding, Stroke | 08/24 | 06/25 | | |
ADVANTAGE AF, NCT05443594: A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation |
|
|
| Active, not recruiting | N/A | 669 | Europe, Canada, US | Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System | Boston Scientific Corporation | Persistent Atrial Fibrillation | 03/25 | 03/25 | | |
| Grant, Marisa |
AVANT GUARD, NCT06096337: Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation |
|
|
| Recruiting | N/A | 387 | Europe, Canada, US, RoW | FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, and Dofetilide | Boston Scientific Corporation | Persistent Atrial Fibrillation | 12/25 | 12/27 | | |
| Then, Leo |
AVANT GUARD, NCT06096337: Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation |
|
|
| Recruiting | N/A | 387 | Europe, Canada, US, RoW | FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, and Dofetilide | Boston Scientific Corporation | Persistent Atrial Fibrillation | 12/25 | 12/27 | | |
